Kissei Pharmaceutical Co., Ltd. (TYO:4547)
3,890.00
+15.00 (0.39%)
May 29, 2026, 3:30 PM JST
Kissei Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 29,057 | 25,169 | 22,894 | 25,893 | 30,013 |
Short-Term Investments | 25,367 | 23,485 | 23,039 | 23,706 | 23,139 |
Cash & Short-Term Investments | 54,424 | 48,654 | 45,933 | 49,599 | 53,152 |
Cash Growth | 11.86% | 5.92% | -7.39% | -6.69% | 19.57% |
Receivables | 31,582 | 28,951 | 27,790 | 22,083 | 21,956 |
Inventory | 25,521 | 24,979 | 26,296 | 22,798 | 18,987 |
Other Current Assets | 3,442 | 4,396 | 4,532 | 6,161 | 5,247 |
Total Current Assets | 114,969 | 106,980 | 104,551 | 100,641 | 99,342 |
Property, Plant & Equipment | 28,091 | 27,069 | 24,861 | 24,579 | 24,074 |
Long-Term Investments | 104,271 | 107,544 | 128,910 | 94,034 | 112,574 |
Goodwill | 176 | 242 | 309 | - | - |
Other Intangible Assets | 1,792 | 1,652 | 1,683 | 1,507 | 1,569 |
Long-Term Deferred Tax Assets | 538 | 566 | 608 | 433 | 524 |
Other Long-Term Assets | 25,245 | 1 | 2 | 1 | 1 |
Total Assets | 275,086 | 244,059 | 260,929 | 221,200 | 238,087 |
Accounts Payable | 6,661 | 4,602 | 4,893 | 4,617 | 4,104 |
Accrued Expenses | 2,427 | 2,192 | 1,856 | 1,679 | 1,721 |
Short-Term Debt | 1,250 | 1,280 | 1,340 | 1,490 | 1,640 |
Current Income Taxes Payable | 5,006 | 1,474 | 2,380 | 408 | 3,497 |
Current Unearned Revenue | 846 | - | - | - | - |
Other Current Liabilities | 5,498 | 7,030 | 7,194 | 6,763 | 7,782 |
Total Current Liabilities | 21,688 | 16,578 | 17,663 | 14,957 | 18,744 |
Pension & Post-Retirement Benefits | 220 | 202 | 209 | 192 | 181 |
Long-Term Deferred Tax Liabilities | 21,029 | 16,481 | 21,188 | 10,426 | 16,259 |
Other Long-Term Liabilities | 614 | 673 | 735 | 812 | 724 |
Total Liabilities | 43,551 | 33,934 | 39,795 | 26,387 | 35,908 |
Common Stock | 24,356 | 24,356 | 24,356 | 24,356 | 24,356 |
Additional Paid-In Capital | 24,243 | 24,226 | 24,226 | 24,226 | 24,226 |
Retained Earnings | 136,253 | 131,488 | 127,310 | 125,576 | 118,183 |
Treasury Stock | -15,513 | -14,520 | -13,209 | -12,912 | -12,912 |
Comprehensive Income & Other | 60,806 | 43,453 | 57,344 | 32,653 | 47,532 |
Total Common Equity | 230,145 | 209,003 | 220,027 | 193,899 | 201,385 |
Minority Interest | 1,390 | 1,122 | 1,107 | 914 | 794 |
Shareholders' Equity | 231,535 | 210,125 | 221,134 | 194,813 | 202,179 |
Total Liabilities & Equity | 275,086 | 244,059 | 260,929 | 221,200 | 238,087 |
Total Debt | 1,250 | 1,280 | 1,340 | 1,490 | 1,640 |
Net Cash (Debt) | 53,174 | 47,374 | 44,593 | 48,109 | 51,512 |
Net Cash Growth | 12.24% | 6.24% | -7.31% | -6.61% | 20.61% |
Net Cash Per Share | 1279.38 | 1086.01 | 985.30 | 1043.24 | 1117.03 |
Filing Date Shares Outstanding | 41.45 | 41.44 | 44.21 | 45.96 | 46.12 |
Total Common Shares Outstanding | 41.45 | 42.81 | 44.21 | 46.12 | 46.12 |
Working Capital | 93,281 | 90,402 | 86,888 | 85,684 | 80,598 |
Book Value Per Share | 5552.08 | 4882.67 | 4977.38 | 4204.63 | 4366.94 |
Tangible Book Value | 228,177 | 207,109 | 218,035 | 192,392 | 199,816 |
Tangible Book Value Per Share | 5504.60 | 4838.42 | 4932.32 | 4171.95 | 4332.92 |
Land | 10,695 | - | - | - | - |
Buildings | 41,745 | - | - | - | - |
Construction In Progress | 543 | - | - | - | - |
Order Backlog | - | 3,403 | 2,613 | 2,098 | 1,479 |